Economic information and modeling reportBudget impact model
Budget impact model discussion
1 evidence topic · 10 sources
Summary: inputs available and absence of a rinzimetostat price or model
No budget impact model of rinzimetostat was identified, and no rinzimetostat price has been published: ORIC has “no products approved for commercial sale”, and its $3.5 billion U.S. addressable market figure “assumes current price of ARPIs for illustrative purposes”. A plan building its own model would need the rinzimetostat price and the regimen studied in Himalayas-1, rinzimetostat 400 mg once daily with darolutamide 600 mg twice daily. Published population inputs are ORIC's estimate of approximately 17,000 U.S. patients annually with mCRPC previously treated with abiraterone (company-reported), a modeled U.S. mCRPC incidence of 42,970 in 2020, and Medicare fee-for-service data in which abiraterone accounted for 36% of first-line mCRPC therapy and 42% of men received at least two lines. Published cost inputs are the darolutamide wholesale acquisition cost of $15,100.80 per bottle of 120 tablets of 300 mg (effective 1 January 2026), the 2027 Medicare negotiated price for enzalutamide of $7,004 per 30-day supply, and Medicare Part B payment limits for October to December 2026 for docetaxel ($0.471 per mg) and cabazitaxel ($231.688 per mg).